Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Monthly Performance Update

21 Aug 2015 07:00

RNS Number : 6803W
BlueCrest AllBlue Fund Ltd
21 August 2015
 



FOR IMMEDIATE RELEASE

 

21 August 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - JULY 2015

 

"Strong gains despite mixed market conditions"

 

BlueCrest AllBlue Fund Limited (BCAB) produced strong gains in July, despite mixed market conditions. BCAB returned 1.8% for the month which brings the year to date return to 2.7% (Sterling Class NAV). The rolling 12 month return was 4.7% and risk measures remained stable.

 

Markets continued to see volatility. Political resolutions in Greece and Iran were overshadowed by a further slump in the Chinese equity market. Economic data was also mixed with generally better data in developed economies offset by worries over Chinese growth and the knock-on effects on commodity prices and other developing economies.

 

"The strongest gains came from systematic funds"

 

All 7 underlying funds rose in July but the strongest gains came from the systematic funds. BlueTrend 2x rose by over 12% (AllBlue now has 5.5% exposure to the 2x leveraged version of BlueTrend) and BlueCrest Quantitative Equity rose by 2.6%.

 

BlueTrend's gains came as more pronounced trends reasserted themselves in markets in July. Particularly strong returns were generated by metals, energy and foreign exchange exposures. Risk levels deployed rose slightly and the model shifted to a net long position in equities during the month and a net short to crops. In other markets, the fund ended the month net long the dollar, fixed income and rates with short positions in metals and energy.

 

BlueCrest Capital International also enjoyed good returns, gaining 1.2% in July. Conditions in developed fixed income markets are increasingly more fruitful and the fund saw particular gains from European trading and cross market strategies. In Europe, the long bias to the short end of the Eurozone was profitable as were the long exposures to Swedish and Swiss rates. All benefited from a "lower for longer" orientation. The allocation committee increased the exposure to BlueCrest Capital International by a further 2% for August to 19%, with a consequent reduction in BlueCrest Quantitative Equity.

 

Despite a treacherous environment in the emerging markets, BlueCrest Emerging Markets Fund recorded a small gain of 0.3% for the month. Conditions, particularly liquidity conditions, were challenging and China dominated sentiment across Asia and into other emerging markets as commodity markets slumped. The fund gained from the China related volatility and also from pricing recovery in CEMEA as the Greek package was finalised.

 

"James Dean appointed to the AllBlue Allocation Committee"

 

James Dean has been appointed to the AllBlue Allocation Committee in place of Matt Weir. Matt is leaving BlueCrest and James is assuming his role as Chief Risk Officer, having been with BlueCrest for 10 years, the last 5 of which have been in the risk department. No changes to controls or processes are occurring.

 

BCAB undertook more repurchases of shares in the market during July as the discount edged out beyond 5%.

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRQBLFLEVFFBBE
Date   Source Headline
31st Jul 201812:16 pmRNSNet Asset Value(s)
30th Jul 20183:51 pmRNSEstimated Creditors Interest
30th Jul 20183:22 pmRNSNet Asset Value(s)
27th Jul 20185:03 pmRNSTransaction in Own Shares
24th Jul 201812:31 pmRNSNet Asset Value(s)
20th Jul 20184:26 pmRNSHolding(s) in Company
17th Jul 20185:35 pmRNSTransaction in Own Shares
17th Jul 20181:52 pmRNSNet Asset Value(s)
11th Jul 20185:02 pmRNSSale of Shares from Treasury
10th Jul 20182:11 pmRNSNet Asset Value(s)
10th Jul 201811:55 amRNSConfirmation of Creditor Payments
6th Jul 20185:52 pmRNSHolding(s) in Company
6th Jul 20185:47 pmRNSSale of Shares from Treasury
5th Jul 20185:01 pmRNSSale of Shares from Treasury
5th Jul 20184:56 pmRNSHolding(s) in Company
4th Jul 201810:03 amRNSNet Asset Value(s)
3rd Jul 201810:38 amRNSHolding(s) in Company
29th Jun 20185:04 pmRNSSale of Shares from Treasury
26th Jun 20181:44 pmRNSNet Asset Value(s)
25th Jun 20185:03 pmRNSSale of Shares from Treasury
25th Jun 201812:12 pmRNSEstimated Creditors Interest
25th Jun 201812:10 pmRNSNet Asset Value(s)
22nd Jun 20185:15 pmRNSSale of Shares from Treasury
22nd Jun 20189:42 amRNSLiquidation of the AllBlue Funds
19th Jun 201811:58 amRNSNet Asset Value(s)
14th Jun 20185:48 pmRNSSale of Shares from Treasury
12th Jun 201812:51 pmRNSNet Asset Value(s)
8th Jun 20184:32 pmRNSSale of Shares from Treasury
5th Jun 201811:40 amRNSInvestor Communication from AllBlue Limited
5th Jun 201811:36 amRNSNet Asset Value(s)
4th Jun 20185:18 pmRNSSale of Shares from Treasury
30th May 201810:51 amRNSNet Asset Value(s)
29th May 20184:44 pmRNSSale of Shares from Treasury
29th May 201812:22 pmRNSEstimated Creditors Interest
29th May 201812:14 pmRNSNet Asset Value(s)
23rd May 201810:00 amRNSNet Asset Value(s)
22nd May 20185:49 pmRNSSale of Shares from Treasury
15th May 201811:36 amRNSNet Asset Value(s)
8th May 201812:02 pmRNSNet Asset Value(s)
3rd May 20183:07 pmRNSNet Asset Value(s)
2nd May 20185:18 pmRNSHolding(s) in Company
30th Apr 20183:49 pmRNSEstimated Creditors Interest
30th Apr 20183:49 pmRNSNet Asset Value(s)
27th Apr 201812:57 pmRNSEstimated Creditors Interest
27th Apr 201812:57 pmRNSNet Asset Value(s)
25th Apr 201812:04 pmRNSEstimated Creditors Interest
25th Apr 201812:00 pmRNSNet Asset Value(s)
24th Apr 20181:30 pmRNSNet Asset Value(s)
24th Apr 201810:03 amRNSEstimated Creditors Interest
24th Apr 20189:39 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.